The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade
出版年份 2020 全文链接
标题
The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade
作者
关键词
-
出版物
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-04-03
DOI
10.1007/s00262-020-02555-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids
- (2019) Akihiro Tokunaga et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
- (2019) Aravindhan Ganesan et al. Scientific Reports
- Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
- (2018) Amber J. Giles et al. Journal for ImmunoTherapy of Cancer
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system
- (2018) Russell Maxwell et al. OncoImmunology
- Nivolumab for the treatment of bladder cancer
- (2017) Oliver W. Hakenberg EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- (2017) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
- (2017) Zin W. Myint et al. Journal of Hematology & Oncology
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling
- (2017) Isobel Okoye et al. Oncotarget
- Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
- (2017) Isobel S. Okoye et al. Frontiers in Immunology
- The promise of immunotherapy in head and neck squamous cell carcinoma
- (2016) P. Economopoulou et al. ANNALS OF ONCOLOGY
- Immune-Related Adverse Events From Immune Checkpoint Inhibitors
- (2016) KA Marrone et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
- (2016) Vincent Sibaud et al. CURRENT OPINION IN ONCOLOGY
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy
- (2015) Kailin Xing et al. BMC IMMUNOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
- (2015) D. S. Thommen et al. Cancer Immunology Research
- Febrile Neutropenia in a Metastatic Melanoma Patient Treated with Ipilimumab - Case Report
- (2015) Sebastian Woźniak et al. Oncology Research and Treatment
- How Steroids Steer T Cells
- (2014) Claude Libert et al. Cell Reports
- Protective HIV-specific CD8+ T cells evade Treg cell suppression
- (2011) Shokrollah Elahi et al. NATURE MEDICINE
- Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
- (2010) Kaan Harmankaya et al. MEDICAL ONCOLOGY
- SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels
- (2009) Ulrike Lorenz IMMUNOLOGICAL REVIEWS
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started